A B S T R A C T Several lysosomal enzymes were assayed in cultured human skin fibroblasts from patients with Duchenne's muscular dystrophy (DMD) and age-and sex-matched control patients (N). The activity of four glycosidases, cathepsin B, and total autoproteolysis at pH 4.0 were unchanged between the groups, but dipeptidyl aminopeptidase I (DAP-I, or cathepsin C) in the DMD cells was found to be only 30% as active as in the control cells (P < 0.003). This difference is not the result of a redistribution or loss of enzyme during homogenization because the difference occurs in all homogenate fractions. DAP-I activity existing in N and DMD fibroblasts behaves identically with respect to activation by chloride ion, activation by the sulfhydryl reducing agent dithiothreitol, changes in hydrogen ion concentration (pH), changes in substrate concentration (i.e., apparent Km values), and changes in temperature (i.e., apparent activation energies). Mixtures of N and DMD cell sonicates display an additivity in DAP-I activity. These results support the conclusion that the catalytic function of the DAP-I molecule is equivalent between N and DMD fibroblasts, and that the decrease in tissuespecific DAP-I activity probably results from the fact that fewer enzyme molecules are present in the DMD cells. These results are also an indication that these nonmuscle cells are expressing some of the phenotypic aspects of the genetic defect in DMD. Cultured human skin fibroblasts may therefore be a useful cellular model in DMD research.
INTRODUCTION
Duchenne's muscular dystrophy (DMD) l is the most prevalent form of the inherited muscular dystrophies and is transmitted as an X-linked recessive gene (1) . The precise metabolic defect underlying the disease process is not yet known. A major obstacle in biochemical studies of dystrophic muscle has been the extensive secondary changes that occur in the degenerating skeletal muscle which serve to obscure the primary error of metabolism. Thus, there are reports of alterations in the levels of DMD skeletal muscle lipids (2, 3) , adenylate cyclase activity (4) (5) (6) , activity of the sarcotubular system (7), protein synthesis (8) , plasma membrane structure (9, 10) and the activity of several lysosomal proteases (11) (12) (13) (14) (15) (16) (17) . The fact that nonmuscle tissues are also affected clinically, although less critically, has suggested that the primary error might also be expressed in other organ systems (1) . For example, circulating erythrocytes from DMD patients have recently been studied to test the hypothesis that the primary lesion in DMD involves a generalized defect in the structure and function of the plasma membrane (1) . The use of erythrocytes as model cells in plasma membrane research is firmly established, but the relative lack of metabolic and substructural complexity of these cells may limit their application to studies of subcellular structures, their membranes, and their related physiological functions.
Cultured fibroblasts obtained from explants of human skin biopsies have proved to be a very useful cell model for investigating a variety of inborn errors of metabolism. These cells possess highly complex structural and functional characteristics that make them suitable for the study of many aspects of cellular metabolism. Studies of cultured fibroblasts from DMD patients have been initiated only very recently, however, and the results reported thus far indicate that the growth characteristics and longevity in culture of these cells is normal (18) , suggesting that study ofthese cells is not subject to the secondary changes imposed by progressive degeneration. There are also reports of altered collagen metabolism and of altered ultrastructural morphology (19, 20) in DMD fibroblasts, but these results were not confirmed in other laboratories (21, 22) . A preliminary report of decreased in vitro protein synthesis with isolated polysomes from DMD fibroblasts also appeared recently (23) . A further indication that the DMD gene is phenotypically expressed in nonmuscle cells comes from the recent finding that lymphocyte capping is defective in DMD patients, DMD carriers, and in certain other primary myopathies (24) .
Our approach to the study of DMD fibroblasts has been to examine the lysosomal characteristics of these cells. During the course of these studies, it was observed that the lysosomal enzyme dipeptidyl aminopeptidase I (DAP-I) (EC 3.4.14.1), also known as "cathepsin C," was on the average only 30% as active in the DMD cells compared with age-and sex-matched control cells. The purpose of this report, therefore, is to fully describe this difference and to present the results of experiments designed to determine whether this effect represents a change in the enzyme resulting in decreased catalytic efficiency of the protein molecule, or whether it represents a secondary change wherein fewer enzyme molecules are present in the DMD cells.
METHODS
Cells. For this study eight lines of fibroblasts from DMD patients and six age-and sex-matched normal controls were used. The sources of the various cell lines and the age and sex of the donors is given in Table I . Six of the DMD lines and four ofthe control lines were obtained from the Repository for Mutant Human Cell Strains, Montreal, Canada. Two ofthe control lines were obtained from the Institute for Medical Research, Camden, N. J., and two of the DMD lines were developed in our laboratory from skin biopsies obtained from patients at the Neurology Clinic of the University of Cincinnati Medical Center. Cells were cultured in 100 x 20 mm Falcon plastic culture dishes (Falcon Labware, Div. Becton, Dickinson & Co., Oxnard, Calif.) in a humidity controlled incubator (Forma Scientific, Div. Mallinckrodt, Inc., Marietta, Ohio) at 37°C and 5% CO2. The growth mediumil (10 mil/plate) consisted of Earle's minimum essential medium (Gibco Laboratories, Grand Island Biological Co., Grand Island, N. Y.) plus 100 U/mi penicillin, 0.1 ug/ml streptomycin, 1% (vol/vol) nonessential amino acids (Gibco Laboratories) 10% (vol/vol) fetal calf serum (Gibco Laboratories), 20 mM Tricine, and 24 mM NaHCO3 (Sigimia Chemical Co., St. Louis, Mo.). Cells were passaged using 0.04% trypsin solution and received fresh medium every 2 d. All cell lines were between passage 10 and 35 during the course of these experiments. The decrease in DMD DAP-I activity was present in the early passage cells and persisted throughout the course of the experiments. For any given experiment, all cell lines were at the same passage number±2. All experiments were done on confluent cells because DAP-I specific activity is lower in log phase cells and increases to a plateau as cells become confluent (data not shown). Special care was taken to handle each cell line separately to avoid crosscontamination of the cultures. All cell lines were tested for mycoplasma and found to be mycoplasma-free at the beginning and end of this study.
Cell disruption. Cells were prepared for enzyme analysis by homogenization, sonication, or freeze-thaw procedure, depending on the particular experiment. For studies of the kinetic characteristics of DAP-I activity, sonication was used to simultaneously disrupt both cells and lysosomes. Cells were rinsed twice with 0.25 M sucrose at 4°C, scraped into 3.0 ml of ice-cold distilled deionized water, and sonicated for 60 s with a Kontes micro-ultrasonic cell disrupter at maximum power. (c) For studies on autoproteolysis, a freeze-thaw procedure was used because preliminary studies showed that this method preserved maximal proteolytic activity (data not shown). Cells were rinsed with ice-cold phosphate-buffered saline, pH = 7.4 and then arginine to label cellular proteins. Cells were harvested, disrupted, and suspended according to the freeze-thaw procedure as described above. The buffered (pH 4.0) suspensions were incubated aerobically at 37°C, and aliquots were removed periodically for analysis of TCA-soluble radioactivity. The aliquots were precipitated in a final TCA concentration (wt/vol) of 10% along with 3 mg/ml of bovine serum albumin added as a carrier protein. The TCAprecipitable and TCA-soluble fractions were separated by centrifugation at 750 g for 10 min at 23°C, aliquots ofthe supernate were solubilized with NCS (Amersham Corp., Arlington Heights, Ill.), and the radioactivity was counted in a PPOtoluene-POPOP scintillation cocktail using a Beckman LS-335 liquid scintillation counter (Beckman Instruments, Fullerton, Calif.). Autoproteolysis was expressed as the percentage ofthe total counts that were TCA-soluble after 3.5 h of incubation at pH 4.0 minus the TCA-soluble activity at the start of the incubation. Under these conditions, autoproteolysis was linear over the first 4 h of incubation and was linear with respect to cell protein concentration (data not shown).
Protein concentration was assayed using the procedure of Lowry et al. (27) with bovine serum albumin serving as standards. The statistical comparisons were based on the twotailed t test (28) . The level of significance chosen was P < 0.05.
RESULTS
The results of various lysosomal assays on normal and DMD fibroblasts are shown in Table II . The activity of four glycosidases and cathepsin B1 were unchanged between the groups. However, DAP-I activity was significantly lower in the DMD population. To test the possibility that this apparent difference might be caused by a redistribution of the enzyme during homogenization, DAP-I activity was assayed in each of the different homogenate fractions (Table III) and was found to be lower in the DMD cells in all cases. The possibility that the lower DAP-I activity observed in the DMD cells might result from increased loss of the enzyme through the plasma membrane and into the surrounding culture medium was also considered. This possibility is unlikely because it was found that DAP-I activity was undetectable in samples of 48-h culture medium from both normal and DMD cells despite use of a highly sensitive fluorometric assay (see Methods). To verify the lysosomal nature of the DAP-I activity, postnuclear supernates were separated on continuous sucrose density equilibrium gradients and the gradient fractions were assayed for DAP-I activity. The sedimentation pattern of DAP-I activity is shown in Fig. 1 as activity per milliliter of aliquot (top panel) and as the percentage of the total enzyme activity in the gradient per aliquot (bottom panel). The data show that although there was less total DAP-I activity in the DMD gradients, the sedimentation pattern was the same between the DMD and normal groups. This sedimentation pattern was identical to that of other characteristic lysosomal enzymes (data not shown), confirming the lysosomal localization of this enzyme.
Individual values for tissue-specific DAP-I activity seen in the left panel of Fig. 2 show that despite the magnitude and the statistical significance ofthe difference between group means, the range of values is very broad, particularly in the normal population. The scattergrams in the three right panels depict DAP-I activity normalized to three other lysosomal enzymes. The rationale for expressing enzyme activity in this way is that the activity of these other lysosomal enzymes may be a more accurate estimate ofthe amount of lysosomal protei'n than the direct measurement of total protein concentration in the crude 30,000 g pellet which contains many other organelles. When DAP-I activity was expressed in this way, the variability was moderately decreased, thereby increasing the statistical significance of the differences in the means of the groups (the P values decreased). The ranges of the two population samples are still seen to overlap in each case, but it should be noted that the overlap is limited to a single point when DAP-I activity is normalized to B3-glucosidase units.
Studies of DAP-I activity purified from other tissues and species (29) DAP-I oct.
DAP-I act. pecific activity) P-glucuronidas oct. P-glucosidase act. 1-golactosidase act. (Fig. 5) . The activity at neutral pH values for DAP-I is not reported here because it is known that DAP-I also catalyzes a "transferase" reaction at neutral and basic pH (29, 30 (Table IV) . (°K-l = 30 -10-4), but above this temperature it is rapidly inactivated. This agrees with reports on the heat inactivation properties of DAP-I from other sources (29) . It can be seen from Fig. 7 that the temperature dependence and the calculated activation energy for DAP-L activity were the same in the normal and DMD cells.
To investigate the possibility that there is a factor in normal cells but not DMD cells that may stimulate DAP-I activity, different mixtures of normal and DMD cell sonicates were prepared. The presence of a stimulator in excess of optimal concentrations in the normal cells but in suboptimal concentrations in DMD cells would be expected to result in a synergistic effect in the mixed-cell sonicates. Table V shows that mixtures of cell preparations from the two groups display a strict additivity in DAP-I activity. These data indicate that the normal cells do not contain an excess of a stimulator of DAP-I activity. However, they do not rule out either the presence of a suboptimal concentration of stimulator or the presence in DMD cells of a noncompetitive inhibitor.
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Because of the probable function of DAP-I as an intracellular protease, its broad substrate specificity, and the possibility that it might be representative of a more general alteration in the protease activity of DMD cells, the total autoproteolytic activity in normal and DMD cells was examined. The effect of pH on the rate of formation of TCA-soluble material from 14C-labeled fibroblast protein and values for the specific autoproteolytic activities of the individual cell lines at pH 4.0 are shown in Fig. 8 . The sharp optimum at pH 4.0 (Fig. 8A) is different from the pH profile of DAP-I (Fig. 5) suggesting that other proteases are responsible for the major portion of the proteolytic activity in these cells. The lack of a significant difference between the autoproteolytic activities of DMD and normal groups (Fig. 8B) indicates that the decreased DAP-I activity in DMD cells is a specific effect rather than part of an overall change in proteolytic activity.
DISCUSSION
The decrease in DAP-I activity in DMD cultured fibroblasts observed in these studies indicates that these cells are metabolically altered in the DMD Table IV ). The presence of a DAP-I stimulator in normal cells can be partially ruled out from the data of Table V showing additivity of mixed DMD and normal cell activities but the presence of suboptimal stimulator levels remains a possibility. On the other hand, it is almost impossible to eliminate the existence of a noncompetitive inhibitor of DAP-I using an unpurified enzyme preparation as was the case in these studies.
It is important to note that all of these experiments on the properties of the fibroblast enzyme have used a nonpurified preparation and could therefore be misleading if the specificity of the glycyl-phenylalanine-,f-naphthylamide assay system were not absolute for DAP-I. However, several facts argue persuasively against this possibility. First, DAP-I has an unusual combination of properties and cofactor requirements, including activity at acid pH, a sulfiydryl requirement, and a highly unusual requirement for chloride ion that is virtually absolute (29) . All of these characteristics were clearly demonstrated in our fibroblast enzyme assay. Second, the fluorogenic substrate used in these studies is generally accepted as being quite specific for DAP-I (29, 32) . Third, DAP-I activity displayed a sedimentation pattern on sucrose density gradients identical to other characteristic lysosomal enzymes, confirming the lysosomal localization of the enzyme. Fourth, we have observed that DAP-I activity displays a latency phenomenon after treatment with detergents that is quantitatively equivalent to the latency characteristics of other lysosomal enzymes (data not shown), further demonstrating the lysosomal character of the fibroblast enzyme. Finally, we have also tested another DAP-I-specific substrate, glycyl-arginine-,8-naphthylamide, and found the same decrease in DMD specific activity with the same statistical validity (data not shown).
Previous investigations on muscle tissue from DMD patients (11) (12) (13) (14) (15) (16) (17) have reported increases in lysosomal protease activity, whereas the results reported here show that total acid autoproteolysis as well as a number of specific lysosomal enzymes are unchanged in DMD fibroblasts. Indeed, one report (13) has shown, contrary to our results on DMD fibroblasts, that DAP-I activity is increased in DMD muscle. The reason for this apparent discrepancy is not clear but it would support the belief that lysosomal "activation" in DMD muscle biopsies is a nonspecific tissue response to injury as opposed to the primary mechanism of cellular degeneration (1) . It is also well known that muscle tissue in DMD patients is undergoing extensive invasion by fibroblasts, macrophages, and fat cells (it is this invasion that gives rise to the pseudohypertrophy characteristic of this disease). The specific activity of DAP-I in human muscle is 36 nM/mg protein per h (13) , whereas in cultured fibroblasts it averages 1,988 and 487 nM/mg protein per h for normal and DMD cells, respectively (our data). Consequently, invasion of DMD muscle by other cells in which only 2-8% of the total cellular protein were replaced by fibroblasts would be sufficient to cause an apparent 100% increase in DAP-I activity. This could therefore account for the observed activation of DAP-I in DMD muscle (13) .
Although the magnitude and statistical significance of the decreased DAP-I activity in DMD fibroblasts reported here are readily apparent, it must be remembered that the range of DAP-I values in the two sample populations of cells does overlap. Thus, decreased fibroblast DAP-I activity per se is probably not a pathognomonic marker for the DMD population. Furthermore, in the absence of any data on other neuromuscular disease control cell lines, it is difficult to assess the specificity of this abnormality. On the other hand, these results do warrant further study of this fibroblast enzyme on larger sample populations so that the precision of the predictive value of this biological indicator can be determined more accurately.
The relationship of the decrease in DAP-I activity in DMD fibroblasts to the overall physiology and metabolism of these cells is presently unknown. The biochemical specificity of the enzyme for cleavage of certain amino terminal dipeptidyl groupings is well characterized (29, 32) but identification of specific physiological protein and/or peptide substrates for the enzyme, the mode of DAP-I regulation and turnover, and the overall role of DAP-I in cellular metabolism are not clear. Further studies of the regulation, turnover, and function of DAP-I in normal and DMD human fibroblasts may yield valuable clues in defining the precise metabolic defect in DMD. Whatever the physiological significance of decreased fibroblast DAP-I activity may be, these results support the suggestion that these nonmuscle cells are expressing at least some of the phenotypic consequences of the genetic defect in DMD.
